IMUX

Immunic Inc

Add to Watchlist

Advanced Chart

0.748

-0.031(-3.980%)1D

Line

Candle

YTD

High

0.7854

Open

0.7849

VWAP

0.74

Vol

2.27M

Mkt Cap

73.80M

Low

0.7262

Amount

1.69M

EV/EBITDA(TTM)

Total Shares

90.08M

21.52M

EV/OCF(TTM)

P/S(TTM)

Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

-0.163

-32.14%

-0.126

-49.72%

-0.120

-52%

Estimates Revision

The market is revising No Change the revenue expectations for Immunic, Inc. (IMUX) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -23.52%.

Revenue Estimates for FY2026

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.96%

In Past 3 Month

Stock Price

Go Down

-23.52%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast IMUX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMUX is 5.33 USD with a low forecast of 3.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.748

Low

3.00

Averages

5.33

High

10.00

Current: 0.748

Low

3.00

Averages

5.33

High

10.00

Ladenburg

Aydin Huseynov

initiated

2025-10-16

Reason

Ladenburg

Aydin Huseynov

Price Target

2025-10-16

initiated

Reason

Ladenburg analyst Aydin Huseynov initiated coverage of Immunic with a Buy rating and $3 price target.

Chardan

Rudy Li

Buy

initiated

$13

2025-09-29

Reason

Chardan

Rudy Li

Price Target

$13

2025-09-29

initiated

Buy

Reason

Chardan analyst Rudy Li initiated coverage of Immunic with a Buy rating and $13 price target. The firm cites the potential of the company's lead asset IMU-838 for the treatment of multiple sclerosis for the Buy rating. The drug has a good chance to report positive data from the ongoing Phase 3 studies, the analyst tells investors in a research note.

B. Riley

William Wood

Buy

downgrade

$6 -> $5

2025-05-23

Reason

B. Riley

William Wood

Price Target

$6 -> $5

2025-05-23

downgrade

Buy

Reason

B. Riley analyst William Wood lowered the firm's price target on Immunic to $5 from $6 and keeps a Buy rating on the shares. The firm updated the company's model post the Q1 report. Riley factored in the prospects of a likely near-term strategic financing to extend Immunic's cash runway well beyond 2026.

B. Riley Securities

William Woods

Strong Buy

Reiterates

2025-04-16

Reason

B. Riley Securities

William Woods

Price Target

2025-04-16

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Matthew Caufield

Strong Buy

Reiterates

$10

2025-04-15

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

$10

2025-04-15

Reiterates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$17

2025-04-10

Reason

D. Boral Capital

Jason Kolbert

Price Target

$17

2025-04-10

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Immunic Inc (IMUX.O) is -1.37, compared to its 5-year average forward P/E of -2.13. For a more detailed relative valuation and DCF analysis to assess Immunic Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.13

Current PE

-1.37

Overvalued PE

-0.59

Undervalued PE

-3.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

10.57

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

89.99

Undervalued EV/EBITDA

-68.85

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1212.57

Current PS

0.78

Overvalued PS

4760.47

Undervalued PS

-2335.34